Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autoimmune disease
Biotech
Sanofi crosses Sjögren's off $5B drug's hit list after phase 2
Sanofi axed Sjögren’s from the list of targeted indications for frexalimab—and reported a phase 3 flop for one of its tarnished former top prospects.
Nick Paul Taylor
Apr 25, 2024 2:35am
Sanofi nails phase 3 LUNA landing, sparking race to regulators
Apr 23, 2024 2:23am
Roivant's inflammatory med is back on track with ph. 2 NIU data
Apr 2, 2024 10:37am
Ginkgo loads up Modulus CAR assets, latest in a string of deals
Apr 2, 2024 7:01am
A new biotech blooms with $100M to take on small molecules
Feb 29, 2024 9:30am
Ono taps Shattuck for $227M bifunctional fusion protein deal
Feb 13, 2024 8:29am